HCV drug sales drag down Gilead's 1Q18 earnings

Gilead Sciences Inc. (NASDAQ:GILD) was off $4.16 to $68.40 in early after-hours trading on Tuesday after reporting 1Q18 earnings that missed analyst estimates for

Read the full 242 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE